Information Provided By: 
Fly News Breaks for July 6, 2015
MDCO
Jul 6, 2015 | 06:46 EDT
Mizuho upgraded The Medicines Co. to Buy and raised its price target to $41 following last week's negative appeals court verdict that leads the way for Angiomax generics near-term. The firm believes consensus estimates still need to come down but believes an overhang has been removed and the focus should be on the company's many new launches and developmental compounds and collaboration potential.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
